Skip to content
value.today

BNB Plus Corp.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Diagnostics and Research: $5 M to $17 M, median $12 MPrice to bookPrice to book of Diagnostics and Research: $7 M to $30 M, median $16 M$0 M$8 M$16 M$25 M$33 M

Your own DCF model

A full discounted-cash-flow model of BNB Plus Corp., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times BNB Plus Corp.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)BNB Plus Corp.Applied toValue (25th to 75th)Companies
Price to sales2.4× / 5.4× / 8.0×—revenue $2 M$5 M to $17 M37
Price to book2.8× / 6.8× / 13.2×—book equity $2 M$7 M to $30 M35

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

BNB Plus Corp.'s multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.

Price to sales

0.7×

Now below its median of 1.9×, in the bottom quarter of its range; range 0.7× to 15.0× over 6 months.

0×4×8×11×15×20202021202220232024Price to sales 1×Median 2×

as of Jan 5, 2024. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Jan 5, 2024.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Sep 30, 2025$2 M$-15 M$-12 M$0 M$-13 M—SEC annual report (10-K, 20-F)
FY2024to Sep 30, 2024$2 M$-7 M$-14 M$0 M$-14 M—SEC annual report (10-K, 20-F)
FY2023to Sep 30, 2023$13 M$-10 M$-6 M$0 M$-6 M—SEC annual report (10-K, 20-F)
FY2022to Sep 30, 2022$18 M$-8 M$-9 M$0 M$-9 M—SEC annual report (10-K, 20-F)
FY2021to Sep 30, 2021$9 M$-14 M$-13 M$3 M$-16 M—SEC annual report (10-K, 20-F)
FY2020to Sep 30, 2020$2 M$-13 M$-11 M$1 M$-12 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.